Nuclide Therapeutics
British BioTech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers
London, UKnuclidetx.com ↗
Total raised
€5.7M
€5,700,000
Funding rounds
1
Investors
1
distinct backers
Active since
2025-09
latest 2025-09
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood33
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-09-23 | Other | €5.7M | Marathon Beteiligungs AG | View deal → |